Christopher Hourigan
#168,068
Most Influential Person Now
Researcher
Christopher Hourigan's AcademicInfluence.com Rankings
Christopher Houriganchemistry Degrees
Chemistry
#5645
World Rank
#6854
Historical Rank
Organic Chemistry
#1021
World Rank
#1151
Historical Rank
Download Badge
Chemistry
Christopher Hourigan's Degrees
- PhD Chemistry University of California, Berkeley
- Bachelors Chemistry University of California, Berkeley
Why Is Christopher Hourigan Influential?
(Suggest an Edit or Addition)According to Wikipedia, Christopher Hourigan is a physician-scientist known for work on measurable residual disease in acute myeloid leukemia. He is the Chief of the Laboratory of Myeloid Malignancies at the National Heart, Lung, and Blood Institute of the National Institutes of Health in Bethesda, Maryland.
Christopher Hourigan's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. (2018) (689)
- Functional Genomic Landscape of Acute Myeloid Leukemia (2018) (639)
- Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. (2020) (303)
- Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. (2019) (204)
- Measurable residual disease testing in acute myeloid leukaemia (2017) (180)
- The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia (2018) (177)
- The Human CD8 Coreceptor Effects Cytotoxic T Cell Activation and Antigen Sensitivity Primarily by Mediating Complete Phosphorylation of the T Cell Receptor ζ Chain* (2001) (174)
- Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis (2017) (166)
- Minimal residual disease in acute myeloid leukaemia (2013) (134)
- Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. (2020) (122)
- Effects of Systemically Administered Hydrocortisone on the Human Immunome (2016) (121)
- 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. (2021) (112)
- Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia (2015) (104)
- A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. (2001) (89)
- Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry. (2018) (85)
- American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. (2020) (82)
- 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party (2021) (75)
- Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. (2017) (64)
- NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome (2017) (62)
- The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation (2019) (58)
- The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches. (2014) (55)
- Immunological effects of hypomethylating agents (2017) (44)
- The molecular basis of coeliac disease (2006) (37)
- Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. (2014) (37)
- Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia. (2015) (37)
- Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia (2018) (35)
- Heterogeneity in refractory acute myeloid leukemia (2019) (34)
- Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. (2021) (33)
- A multigene array for measurable residual disease detection in AML patients undergoing SCT (2015) (31)
- Pathogenic TERT promoter variants in telomere diseases (2018) (31)
- Baseline TP53 mutations in Adults with SCD developing Myeloid Malignancy following Hematopoietic Cell Transplantation. (2020) (31)
- Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy (2017) (31)
- Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations (2021) (30)
- Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues (2014) (30)
- Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia (2018) (28)
- Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. (2014) (27)
- Adult Acute Myeloid Leukemia Long-term Survivors. (2014) (26)
- Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemia (2019) (26)
- Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation (2019) (25)
- Identification of novel microRNA signatures linked to acquired aplastic anemia (2015) (23)
- MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations. (2019) (23)
- Functional genomic landscape of acute myeloid leukaemia (2018) (22)
- Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia (2021) (22)
- Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia (2017) (22)
- Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy (2013) (22)
- Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. (2016) (22)
- Barrett's, blood groups and progression to oesophageal cancer: is nitric oxide the link? (2011) (22)
- Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. (2022) (21)
- Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia. (2020) (21)
- When the Minimal Becomes Measurable. (2016) (21)
- MRD evaluation of AML in clinical practice: are we there yet? (2019) (20)
- Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (2018) (18)
- Evaluation of current cancer immunotherapy: hemato-oncology. (2011) (18)
- The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia (2017) (17)
- Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia. (2017) (16)
- Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response (2018) (14)
- Precision medicine for acute myeloid leukemia (2016) (14)
- The structure of the human allo‐ligand HLA‐B*3501 in complex with a cytochrome p450 peptide: Steric hindrance influences TCR allo‐recognition (2006) (13)
- Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice (2018) (13)
- Development of therapeutic agents for older patients with acute myelogenous leukemia. (2010) (13)
- Repair of impaired pulmonary function is possible in very-long-term allogeneic stem cell transplantation survivors. (2014) (12)
- Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis. (2021) (12)
- Personalized therapy for acute myeloid leukemia. (2013) (10)
- Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome (2020) (10)
- Cells of myeloid origin partly mediate the association between psoriasis severity and coronary plaque. (2020) (9)
- Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. (2021) (9)
- Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation (2019) (9)
- Age is no Barrier for Adults undergoing HCT for AML in CR1: Contemporary CIBMTR Analysis (2022) (8)
- An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis (2021) (8)
- Contrast enhanced cardiac CT reveals coronary artery disease in 45% of asymptomatic allo-SCT long-term survivors (2014) (8)
- New considerations in the design of clinical trials for the treatment of acute leukemia. (2011) (8)
- Successful salvage chemotherapy and allogeneic transplantation of an acute myeloid leukemia patient with disseminated Fusarium solani infection (2017) (7)
- Clinical and biological predictors of outcome following relapse of CML post-allo-SCT (2015) (6)
- A Novel Approach to Antigen-Specific Deletion of CTL with Minimal Cellular Activation Using a 3 Domain Mutants of MHC Class I / Peptide Complex express (2001) (6)
- Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia (2019) (6)
- Allogeneic Transplantation to Treat Therapy Related MDS and AML in Adults. (2021) (6)
- Myeloid Leukemias Directly Suppress T Cell Proliferation Through STAT3 and Arginase Pathways (2013) (6)
- Detectable mutations precede late myeloid neoplasia in aplastic anemia (2020) (6)
- Refining AML outcome prediction (2018) (6)
- Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis (2020) (6)
- Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. (2019) (5)
- Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects (2020) (5)
- Pre-MEASURE: Multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission. (2022) (5)
- The present and future of measurable residual disease testing in acute myeloid leukemia (2022) (5)
- T Cell Exhaustion and Downregulation of Cytotoxic NK Cells – an Immune Escape Mechanism in Adult Acute Lymphoblastic Leukemia (2014) (5)
- Next generation MRD. (2014) (5)
- Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia. (2022) (5)
- Corrigendum: Effects of Systemically Administered Hydrocortisone on the Human Immunome (2016) (5)
- A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission. (2017) (5)
- DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. (2023) (4)
- Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis (2022) (4)
- Increased Frequencies of PD-1+ CD8+ Marrow-Infiltrating Lymphocytes Associated with Highly Clonal T-Lymphocyte Expansions in Relapsed and Refractory AML Patients but Not Healthy Adults (2016) (4)
- A single-center survey of health-related quality of life among acute myeloid leukemia survivors in first complete remission. (2016) (4)
- Registering organ donor preferences - a third way? (2005) (4)
- Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma (2013) (4)
- Utility of plasma cell-free DNA for de novo detection and quantification of clonal hematopoiesis (2021) (4)
- Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes (2022) (4)
- CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation (2016) (4)
- Clinical and Biological Predictors of Outcome Following Relapse of Chronic Myeloid Leukemia after Allogeneic Stem Cell Transplantation (2014) (4)
- Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative (2022) (4)
- The splicing factor U2AF1 contributes to cancer progression through a non-canonical role in translation regulation (2018) (3)
- How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines. (2023) (3)
- Genetically determining individualized clinical reference ranges for the biomarker tryptase can limit unnecessary procedures and unmask myeloid neoplasms (2022) (3)
- An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). (2022) (3)
- Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults (2020) (3)
- Clinical comorbidity predictive measures in ex vivo T-cell-depleted allogeneic hematopoietic stem cell transplantation (2015) (3)
- Reprint of: Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. (2014) (3)
- Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism. (2022) (3)
- Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML (2021) (3)
- Editorial: Targets for Immunotherapy in Acute Leukemia. (2017) (2)
- Comparison of Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide to Matched-Sibling, Matched-Unrelated, Mismatched-Unrelated, and Umbilical Cord Blood Donor Transplantation in Adults with Acute Lymphoblastic Leukemia: A CIBMTR Study (2020) (2)
- Cord-Blood Transplantation in Patients with Minimal Residual Disease. (2016) (2)
- Leukaemia risk associated with low-dose radiation. (2018) (2)
- Altered microRNAs in T Cells from Patients with Acquired Aplastic Anemia (2014) (1)
- Alemtuzumab Is Safe and Associated With High Response Rates In Selected Patients With Myelodysplastic Syndrome (2013) (1)
- Evaluation of a Rapid Automated Next Generation Sequencing Assay for Precision Medicine in Acute Myeloid Leukemia (2021) (1)
- Human Bone Marrow Assessment by Single Cell RNA Sequencing, Mass Cytometry and Flow Cytometry (2018) (1)
- Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (2014) (1)
- B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia (2020) (1)
- Accurate Medicine: Indirect Targeting of NPM1-Mutated AML. (2016) (1)
- Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy. (2021) (1)
- Prompt CR Plus Consolidation Therapy Yields Improve Survival after Allogeneic Transplantation for AML Patients Receiving Myeloablative, but Not Reduced-Intensity Conditioning: A CIBMTR Analysis (2021) (1)
- High Levels Of IL-27 Occur In Newly Diagnosed Acute Myeloid Leukemia (AML) and May Influence Outcome By Suppressing T Cell Function (2013) (1)
- Acute Myeloid Leukemia: Introduction. (2015) (1)
- Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial) (2022) (1)
- Achieving MRD negativity in AML: how important is this and how do we get there? (2022) (1)
- Pre-MEASURE: FLT3-ITD and mutated NPM1 measurable residual disease before allogeneic transplant in adults with AML in first remission (2022) (1)
- Targets For Immunotherapy In Acute Leukemia. (2015) (1)
- A Novel Multi-Gene Array Allows Relapse Risk Stratification in Acute Myeloid Leukemia Patients Undergoing Stem Cell Transplantation (2014) (1)
- A Novel Multi-Gene Expression Array Allows Highly Sensitive Detection Of Minimal Residual Disease and Predicts Relapse Outcomes In Acute Myeloid Leukemia (2013) (1)
- Development of Somatic NRAS Mutation Associated with Rapid Transition from Germline GATA2 Mutation Associated Myelodysplastic Syndrome to Acute Myeloid Leukemia (2015) (1)
- Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review (2021) (1)
- The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis (2016) (1)
- Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis (2022) (0)
- A Novel Proteomic Profiling of the Bone Marrow Microenvironment Reveals Elevated Levels of the Chemokine CCL23 Isoforms in Acute Myeloid Leukemia (2019) (0)
- Assessment of Next Generation Sequencing Approaches for the Cytogenetic and Molecular Evaluation of Acute Myeloid Leukemia (2021) (0)
- Abstract 3756: Highly multiplexed proteomic assessment of the human acute myeloid leukemia bone marrow microenvironment (2019) (0)
- Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). (2023) (0)
- Spatial-Temporal Multiomic Analysis of Tumor-Immune Interactions in Patients with AML Receiving Pembrolizumab and Decitabine (2022) (0)
- Recent advances in the understanding and treatment of acute myeloid leukemia (2019) (0)
- Whole Genome Sequencing Uncovers a Rare Germline Variant in ATM Associated with Familial Myeloproliferative Neoplasms (2021) (0)
- Allogeneic Blood or Marrow Transplantation with High-Dose Post-transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Aged ≥55. (2022) (0)
- Pathogenic TERT promoter variants in telomere diseases (2018) (0)
- Post-Transplant Pulmonary Function Abnormalities Nadir At Five Years and Then Fully Normalize by the Second Decade in Allogeneic Stem Cell Transplantation Survivors (2013) (0)
- Evaluation of Current Cancer Immunotherapy (2011) (0)
- Minimal Residual Disease in Acute Myeloid Leukemia (2014) (0)
- Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy (2017) (0)
- Pre- and Post-Transplant Measurable Residual IDH Mutations Are Not Associated with Relapse in Patients with IDH-Mutated AML (2022) (0)
- Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms (2022) (0)
- A Prospective Pilot Study to Evaluate Molecular Changes in the Hematopoietic System after Receipt of Chemotherapy or Radiotherapy and Its Clinical Implications Among Racially Diverse Breast Cancer Survivors: Breast Survivorchip Study (2020) (0)
- Duplex Sequencing Accurately Detects Variants below 1/100,000 in Genes Recurrently Mutated in Acute Myeloid Leukemia (2018) (0)
- Immunophenotypic Patterns of Bone Marrow Eosinopoiesis in Patients with Hypereosinophillic Syndrome and Systemic Mastocytosis (2018) (0)
- Are medical schools fit for graduates? (2005) (0)
- CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation (2014) (0)
- Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct (2015) (0)
- Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification (2022) (0)
- Impaired Response to Influenza Vaccination in AML Patients Post-Chemotherapy Associated with a Highly Atypical B-Cell Profile (2015) (0)
- Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia (2023) (0)
- Prediction of HLA genotypes from single-cell transcriptome data (2022) (0)
- Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients. (2023) (0)
- Duplex Sequencing for Ultra-Low Frequency Measurable Residual Disease Detection in Adult Acute Myeloid Leukemia (2021) (0)
- Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC) (2022) (0)
- Molecular testing during AML treatment for early prediction of clinical response. (2018) (0)
- Support for the paediatric intensive care nurse when a child dies (1996) (0)
- Gemtuzumab Ozogamicin for Cytoreduction in Hyperleukocytosis (2022) (0)
- 250 Spatial-transcriptomic analysis of tumor-immune microenvironment in AML patients receiving pembrolizumab and decitabine (2021) (0)
- Multigene MRD Assessment Improves AML Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation (2015) (0)
- Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia (2023) (0)
- Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab (2021) (0)
- Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia (2014) (0)
- Abstract 422: Duplex sequencing for MRD detection in acute myeloid leukemia (2019) (0)
- Systematic analysis of potential targets for immunotherapy in acute myeloid leukemia. (2013) (0)
- The Clinical and Financial Cost of Preemptive Management of CMV Disease – Implications for Immunotherapy (2014) (0)
- Single-Cell Transcriptomic and Proteomic Analysis of Acute Myeloid Leukemia (AML) Patients with Abnormalities on Chromosome 7 (2021) (0)
- Cardiac CT Imaging Is a Feasible Screening Strategy for Coronary Artery Disease (CAD) in Long Term Allogeneic Stem Cell Transplant (Allo-SCT) Survivors (2015) (0)
- Insights Into Crossreactivity in Human Allorecognition: The Structure of HLA-B35011 Presenting an Epitope derived from Cytochrome P450. (2006) (0)
- Abstract CT138: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes (2021) (0)
- Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies (2020) (0)
- Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms (2022) (0)
- Highly Multiplexed Cell Surface Immunophenotyping with Genotyping and Concurrent Transcriptomic Analysis of NPM1 mutated Acute Myeloid Leukemia (2021) (0)
- Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. (2022) (0)
- Contrast Enhanced Cardiac CT Detects Coronary Artery Disease In 44% Of Asymptomatic Long-Term Adult Allogeneic Stem Cell Transplant Survivors (2013) (0)
- Post-Transplant Pulmonary Function Abnormalities Normalize in Survivors by the Second Decade After Allogeneic Stem Cell Transplantation (2012) (0)
- Myeloid-Derived Suppressor Phenotype of Leukemic Blasts in Association with Increased Suppressor T Cell Subsets in Acute Myelogenous Leukemia– Evidence for Immunoediting. (2012) (0)
- Preventing relapse post-transplant: When and how to best intervene? (2017) (0)
- Faculty Opinions recommendation of Prediction of acute myeloid leukaemia risk in healthy individuals. (2018) (0)
- IN THE SPOTLIGHT Personalized Therapy for Acute Myeloid Leukemia (2013) (0)
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Blastic Plasmacytoid Dendritic Cell Neoplasm: A CIBMTR Analysis (2022) (0)
- Ph-Positive ALL Patients Who Are Treated with Tyrosine Kinase Inhibitors Have Similar Post-Transplant Survival As Ph-Negative Patients (2023) (0)
- Abstract A071: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes (2019) (0)
- Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL (2020) (0)
- Haplo, we have a problem. (2017) (0)
- Somatic TERT promoter Mutations in a Broad Spectrum of Telomeropathies (2018) (0)
This paper list is powered by the following services:
Other Resources About Christopher Hourigan
What Schools Are Affiliated With Christopher Hourigan?
Christopher Hourigan is affiliated with the following schools:
